Weight gain in antipsychotic-naive patients: a review and meta-analysis

2009 ◽  
Vol 40 (2) ◽  
pp. 187-200 ◽  
Author(s):  
I. Tarricone ◽  
B. Ferrari Gozzi ◽  
A. Serretti ◽  
D. Grieco ◽  
D. Berardi
Keyword(s):  
Body Weight ◽  
Weight Gain ◽  
High Probability ◽  
Drug Exposure ◽  
Meta Analysis ◽  
Health Concern ◽  
Adjunctive Treatment ◽  
Review Of The Literature ◽  
Major Health ◽  
The Mean

BackgroundWeight gain is a long-recognized side-effect of antipsychotic (AP) drugs and a major health concern in the treatment of psychosis. The strength of the causal relationship between AP drug exposure and weight gain can only be gauged by a drugs trial conducted on AP-naive patients.MethodWe conducted a review of the literature regarding the amount of weight gain induced by APs in AP-naive patients and carried out a meta-analysis of mean weight gains.ResultsWe found 11 primary studies reporting the effects of APs on body weight or body mass index (BMI) in AP-naive patients. The mean body weight and BMI gains in AP-naive patients were highly significant from the first weeks of treatment. When we limited the analysis to studies conducted on patients hospitalized and without any adjunctive treatment potentially affecting weight, the resultant sample showed less heterogeneity and confirmed the final picture of weight gain at around 3.8 kg and 1.2 points BMI.ConclusionsWeight gain associated with AP therapy in AP-naive patients occurs rapidly in the first few weeks and continues during the following months. Clinicians should be aware of the high probability of causing weight gain in AP-naive patients and should strictly monitor such patients.

scholarly journals Effects of Different Integrase Inhibitors on Body Weight in Patients with HIV/AIDS: A Network Meta-Analysis

2020 ◽  
Author(s):  
Ruojing Bai ◽  
Shiyun Lv ◽  
Hao Wu ◽  
Lili Dai
Keyword(s):  
Body Weight ◽  
Weight Gain ◽  
Meta Analysis ◽  
Biomedical Literature ◽  
Cochrane Library ◽  
Weight Changes ◽  
Aids Patients ◽  
First Choice ◽  
Significant Difference ◽  
Hiv Aids

Abstract Background: Global antiretroviral therapy has entered the era of integrase strand transfer inhibitor (INSTI). Because INSTIs have the advantages of high antiviral efficacy, rapid virus inhibition, and good tolerance, they have become the first choice in international acquired immunodeficiency syndrome (AIDS) treatment guidelines. However, they may also increase the risk of obesity. There are differences in the effects of different INSTIs on weight gain in Human immunodeficiency virus (HIV) infection / AIDS patients, but there is no evidence-based medical evidence. This study aimed to assess the effect of different INSTIs on body weight in HIV/AIDS patients.Methods: PubMed, Embase, Cochrane Library, China National Knowledge Infrastructure (CNKI), Chinese Biomedical Literature Database (CBM), China Science and Technology Journal Database, and Wanfang databases were searched by computer to screen the relevant literature on INSTI treatment of HIV/AIDS patients, extract the data on weight changes in the literature, and perform network meta-analysis using Stata16.0 software.Results: Eight articles reported weight changes in HIV/AIDS patients, and weight gain was higher after treatment with dolutegravir (DTG) than with elvitegravir (EVG) in HIV/AIDS patients, and the difference was statistically significant [MD = 1.13, (0.18, 2.07)]. The network meta-analysis's consistency test results showed no overall and local inconsistency, and there was no significant difference in the results of the direct and indirect comparison (P > 0.05). The rank order of probability was DTG (79.2%) > Bictegravir (BIC) (77.9%) > Raltegravir (RAL) (33.2%) > EVG (9.7%), suggesting that DTG may be the INSTI drug that causes the most significant weight gain in HIV/AIDS patients.Conclusion: According to the literature data analysis, among the existing INSTIs, DTG may be the drug that causes the highest weight gain in HIV/AIDS patients, followed by BIC.

scholarly journals Effect of dietary supplementation of biofloc meal on growth and survival of GIFT tilapia

2018 ◽  
Vol 65 (1) ◽  
Author(s):  
E. Prabu ◽  
C.B.T Rajagopalsamy ◽  
B. Ahilan ◽  
Jegan Michael Andro Jeevagan ◽  
M. Renuhadevi
Keyword(s):  
Body Weight ◽  
Weight Gain ◽  
Body Weight Gain ◽  
Dietary Supplementation ◽  
Feed Conversion ◽  
Efficiency Ratio ◽  
Growth And Survival ◽  
Commercial Diet ◽  
Gift Tilapia ◽  
The Mean

A 60 days indoor growth trial was conducted to study the effect of dietary supplementation of biofloc meal on growth and survival of juvenile GIFT tilapia. Four isonitrogenous and isoenergetic experimental diets (32% crude protein) were prepared using biofloc meal at different inclusion levels viz., 0 (T0), 20 (T1), 30 (T2) and 40% (T3). A commercial diet (T4) was used for comparison. The feeding trial was conducted in 15 nos. of 40 l plastic troughs in triplicate, utilising GIFT tilapias weighing an average of 2 g. During the experimental period, water quality parameters were measured and recorded daily. The mean value of water temperature, pH, dissolved oxygen, salinity, ammonia-N, nitrite-N, nitrate-N, hardness and alkalinity recorded in the experimental systems were 28.5°C, 8.1, 5.5 ppm, 4.5 ppt, 0.03 ppm, 0.07 ppm, 11 ppm, 630 ppm and 162.5 ppm respectively. Among the biofloc meal enriched diets, diet T1 with 20% biofloc yielded the best results in terms of average body weight gain, feed conversion ratio (FCR), specific growth rate (SGR), protein efficiency ratio (PER) and feed efficiency ratio (FER). The mean body weight gain recorded in T1 was 25.28±0.81 g. The results demonstrated that biofloc meal is a potential ingredient that can be incorporated in GIFT tilapia diet at 20% level for better growth performance.

scholarly journals CoMET: a protocol for a randomised controlled trial of co-commencement of METformin as an adjunctive treatment to attenuate weight gain and metabolic syndrome in patients with schizophrenia newly commenced on clozapine

BMJ Open ◽  
2018 ◽  
Vol 8 (3) ◽  
pp. e021000 ◽  
Author(s):  
Dan Siskind ◽  
Nadia Friend ◽  
Anthony Russell ◽  
John J McGrath ◽  
Carmen Lim ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Body Weight ◽  
Weight Gain ◽  
Controlled Trial ◽  
Adjunctive Treatment ◽  
Double Blind ◽  
Human Research Ethics ◽  
Increased Risk ◽  
Point Body ◽  
Randomised Controlled

IntroductionClozapine, while effective in treatment refractory schizophrenia, is associated with significant weight gain, heart disease and increased risk of type 2 diabetes mellitus (T2DM). Although there is evidence for weight loss with metformin for people with obesity who are already taking clozapine, there have been no published trials that have investigated the effect of metformin in attenuating weight gain at the time of clozapine initiation.Methods and analysisA 24-week double-blind placebo-controlled trial of concomitant prescription of metformin at clozapine commencement. Eighty-six people being commenced on clozapine will be randomised to placebo or metformin (variable dose, up to 2 g/day). The primary outcome is comparative end point body weight, between the placebo and metformin groups. Secondary outcomes are comparative rates of conversion to T2DM, alteration of metabolic syndrome parameters, proportion gaining >5% body weight and changes in diet and appetite. We will additionally examine biomarkers associated with change in weight among trial participants.Ethics and disseminationEthics approval was granted by the Metro South Human Research Ethics Committee HREC/17/QPAH/538-SSA/17/QPAH/565. We plan to submit a manuscript of the results to a peer-reviewed journal, and present results at conferences, consumer forums and hospital grand rounds.Trial registration numberACTRN12617001547336; Pre-results.

scholarly journals Genes associated with body weight gain and feed intake identified by meta-analysis of the mesenteric fat from crossbred beef steers

PLoS ONE ◽  
2020 ◽  
Vol 15 (1) ◽  
pp. e0227154
Author(s):  
Amanda K. Lindholm-Perry ◽  
Harvey C. Freetly ◽  
William T. Oliver ◽  
Lea A. Rempel ◽  
Brittney N. Keel
Keyword(s):  
Body Weight ◽  
Weight Gain ◽  
Feed Intake ◽  
Body Weight Gain ◽  
Meta Analysis ◽  
Beef Steers ◽  
Mesenteric Fat

Influence of Intestinal Microbiota on Body Weight Gain: a Narrative Review of the Literature

2014 ◽  
Vol 25 (2) ◽  
pp. 346-353 ◽  
Author(s):  
Camila S. Cardinelli ◽  
Priscila C. Sala ◽  
Claudia C. Alves ◽  
Raquel S. Torrinhas ◽  
Dan L. Waitzberg
Keyword(s):  
Body Weight ◽  
Weight Gain ◽  
Intestinal Microbiota ◽  
Body Weight Gain ◽  
Narrative Review ◽  
Review Of The Literature

scholarly journals Clinical examination of weanling rats with early zinc deficiency

1989 ◽  
Vol 23 (4) ◽  
pp. 328-332 ◽  
Author(s):  
H. Van Herck ◽  
J. P. Van Wouwe ◽  
M. Veldhuizen ◽  
V. Baumans ◽  
F. R. Stafleu ◽  
...  
Keyword(s):  
Body Weight ◽  
Weight Gain ◽  
Zinc Deficiency ◽  
Clinical Examination ◽  
Body Weight Gain ◽  
Individual Animal ◽  
Deficient Diet ◽  
Weanling Rats ◽  
The Mean ◽  
Zinc Deficient Diet

In order to gain experience about the detection of adverse effects during a scientific procedure, we carried out a clinical examination of rats with zinc deficiency. In weanling rats fed a zinc-deficient diet (30 μmol zinc/kg) for 10 days, the mean tibial concentration of zinc was reduced by 53% and body weight gain by 73070 when compared with rats fed a diet containing an adequate amount of zinc (150 μmol zinc/kg). In a small open field on day 9 of the experiment, the deficient rats more frequently displayed the posture standing upright with elevated heels. On day 10 of the experiment a clinical examination was carried out at random and 'blind' by three independent assessors. Out of 20 variables scored quantitatively on each individual animal, only body size differed between normal and deficient rats. Other classical signs of zinc deficiency, such as alopecia, dermatitis and diarrhoea, were not detected. It is concluded that in this rat model of zinc deficiency, no evidence for extreme discomfort can be demonstrated.

Body weight gain and risk of colorectal cancer: a systematic review and meta-analysis of observational studies

2015 ◽  
Vol 16 (7) ◽  
pp. 607-619 ◽  
Author(s):  
S. Schlesinger ◽  
W. Lieb ◽  
M. Koch ◽  
V. Fedirko ◽  
C. C. Dahm ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Systematic Review ◽  
Body Weight ◽  
Weight Gain ◽  
Observational Studies ◽  
Body Weight Gain ◽  
Meta Analysis

scholarly journals The Effect of Fermented Sago Pulp on Performances and Income Over Feed Cost (IOFC) Local Sheep

2018 ◽  
Vol 6 (1) ◽  
Author(s):  
Mustapa Zahri Ritonga ◽  
Hasnudi ◽  
Iskandar Sembiring ◽  
Tri Hesti Wahyuni ◽  
Nevy Diana Hanafi
Keyword(s):  
Body Weight ◽  
Weight Gain ◽  
Body Weight Gain ◽  
Daily Weight Gain ◽  
Feed Consumption ◽  
Feed Conversion ◽  
Real Effect ◽  
Feed Cost ◽  
Randomized Design ◽  
The Mean

This study aims to determine the effect of fermented sago pulp in rations on performance (weight gain, feed consumption, feed conversion) and local sheep's income over feed cost (IOFC). This research was carried out in the community farms of Karang Rejo Village, Stabat District, Langkat Regency. This research started from March to June 2017. The design used was complete randomized design (RAL), with 4 treatment of 5 replications. Each replication consisted of 1 local sheep with an initial weight of 11.05 ± 0.56 kg. The treatment consisted of P1 (50% sago pulp without fermentation + forage), P2 (60% of sago pitch without fermentation + forage), P3 (50% fermented sago pulp + forage), and P4 (60% fermented sago pulp +). The observed variables were performance (body weight gain, feed consumption, feed conversion) and income over feed cost (IOFC). The results showed that the treatment of fermented sago pulp gave a very real effect (P <0.01) on daily weight gain. The mean of P1 = 33,05 g, P2 = 39,95 g, P3 = 46,57 g, P4 = 54,38g. The consumption of fermented sago pulp treatment has a real effect (P <0,01). With average P1 = 486,38 g, P2 = 548,68 g, P3 = 604,69 g, P4 = 671,11 gr. Against the conversion of fermented sago pulp fermentation treatment gave a real effect (P <0.05). With average P1 = 14.78, P2 = 13.90, P3 = 12.99, P4 = 12,49. IOFC the highest local sheep is Rp. 121.568 on treatment of P4 and IOFC lowest at treatment P1 equal to Rp.73.315. The conclusion of the research shows that the utilization of fermented sago pulp can increase body weight gain, feed consumption, local sheep feed conversion. P4 treatment economically has a better economic level than P1,P2 and P3.

scholarly journals FEED UTILIZATION BY BROILER CHICKENS FED THREE COMMERCIAL MICRONUTRIENT PREMIXES AT TWO PHYSIOLOGICAL STAGES OF GROWTH

2021 ◽  
Vol 23 (2) ◽  
pp. 129-133
Author(s):  
O. O. ODUGUWA ◽  
B. K. OGUNMODEDE ◽  
A. O. FANIMO
Keyword(s):  
Growth Rate ◽  
Body Weight ◽  
Weight Gain ◽  
Treatment Group ◽  
Broiler Chickens ◽  
Feed Utilization ◽  
Daily Weight Gain ◽  
Poor Growth ◽  
Stages Of Growth ◽  
The Mean

Three commercial premix types were fed in and duplicated to six groups of 45 broilers each at the starter pbase (0-5 weeks). At the finisher phase (5-9 weeks) each treatment group of the vital roles in starter was further divided into three groups. Nine premix combinations were used at the finisher pbase. Performance of the birds was monitored. At the starter phase, birds fed premix Z diet had a mean body weight blood (629.90gm) that was higher (P<0.05) than fed premix A diet (518.87 gm) which was also the maintenance of osmotic relations and acid higher than those fed premix U diet (414.59gm). The mean daily weight gain followed the same  trend with 16.81gm, 14.04gm, or 10.58 gm for birds fed diets that contained premixes Z A or U respectively. Birds fed a diet that contained premix Z consumed 48.80 gm daily which was  more than those for birds fed premix U in their diet (37.85gm). The feed to gain ratio was not significantly affected (P>0.05) by the premix  type fed at this phase. Poor growth rate caused by premixes with marked differences in their by premix fed at the starter phase was not completely overcome due to the premix type fed at the finisher phase varied (P<0.05) with the type of premix fed. No difference (P>0.05) was observed among the  premix types for the metabolic trials at the starter phase.

scholarly journals Association Between Breakfast Skipping and Body Weight – a Systematic Review and Meta-Analysis of Observational Longitudinal Studies

2020 ◽  
Author(s):  
Julia Wicherski ◽  
Sabrina Schlesinger ◽  
Florian Fischer
Keyword(s):  
Systematic Review ◽  
Body Weight ◽  
Weight Gain ◽  
Longitudinal Studies ◽  
Weight Change ◽  
Meta Analysis ◽  
Cross Sectional ◽  
Breakfast Skipping ◽  
Increased Risk ◽  
Meta Analyses

Globally, increasing rates of obesity are one of the most important health issues. The association between breakfast skipping and body weight is contradictory between cross-sectional and interventional studies. The systematic review and meta-analyses aim to summarize this association based on observational longitudinal studies. We included prospective studies on breakfast skipping and overweight/obesity or weight change in adults. Literature was searched until September 2020 in PubMed and Web of Science. Summary RRs with a 95% CI were estimated in pairwise meta-analyses by applying a random-effects model. In total, 9 studies were included in the systematic review and 6 of them were included in the meta-analyses. The meta-analysis indicated an 13% increased RR for overweight/obesity when breakfast was skipped on &ge; 3 days per week compared to &le; 2 days per week (95% CI: 1.06, 1.21, n=3 studies). The meta-analysis on weight change displays a 21% increased RR for weight gain for breakfast skippers compared to breakfast eaters (95% CI: 1.05, 1.40, n=2 studies). The meta-analysis on BMI change displayed no difference between breakfast skipping and eating (RR=1.02, 95% CI: 0.99, 1.05, n=2 studies). This study provides low meta-evidence for an increased risk for overweight/obesity and weight gain for breakfast skipping.

Sign in / Sign up

Export Citation Format

Share Document